Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar;44(3):293-309.
doi: 10.1007/s12272-021-01318-6. Epub 2021 Mar 24.

Treatments of inflammatory bowel disease toward personalized medicine

Ki-Uk Kim  1 , Jisu Kim  1 , Wan-Hoon Kim  1 , Hyeyoung Min  2 , Chang Hwan Choi  3
Affiliations
Review

Treatments of inflammatory bowel disease toward personalized medicine

Ki-Uk Kim et al. Arch Pharm Res. 2021 Mar.

Abstract

Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), is a chronic inflammatory disease characterized by intestinal inflammation and epithelial injury. For the treatment of IBD, 5-aminosalicylic acids, corticosteroids, immunomodulators, and biologic agents targeting tumor necrosis factor (TNF)-α, α4β7-integrin, and interleukin (IL)-12/23 have been widely used. Especially, anti-TNF-α antibodies are the first biologic agents that presently remain at the forefront. However, 10-30% of patients resist biologic agents, including anti-TNF-α agents (primary non-responder; PNR), and 20-50% of primary responders develop treatment resistance within one year (secondary loss of response; SLR). Nonetheless, the etiologies of PNR and SLR are not clearly understood, and predictors of response to biologic agents are also not defined yet. Numerous studies are being performed to discover prediction markers of the response to biologic agents, and this review will introduce currently available therapeutic options for IBD, biologics under investigation, and recent studies exploring various predictive factors related to PNR and SLR.

Keywords: Biologic agent; Crohn’s disease; Inflammatory bowel disease; Personalized medicine; Ulcerative colitis.

PubMed Disclaimer

References

    1. Aden K, Rehman A, Waschina S, Pan WH, Walker A, Lucio M, Nunez AM, Bharti R, Zimmerman J, Bethge J, Schulte B, Schulte D, Franke A, Nikolaus S, Schroeder JO, Vandeputte D, Raes J, Szymczak S, Waetzig GH, Zeuner R, Schmitt-Kopplin P, Kaleta C, Schreiber S, Rosenstiel P (2019) Metabolic functions of gut microbes associate with efficacy of tumor necrosis factor antagonists in patients with inflammatory bowel diseases. Gastroenterology 157:1279-1292.e1211. https://doi.org/10.1053/j.gastro.2019.07.025 - DOI - PubMed
    1. Almradi A, Hanzel J, Sedano R, Parker CE, Feagan BG, Ma C, Jairath V (2020) Clinical trials of IL-12/IL-23 inhibitors in inflammatory bowel disease. BioDrugs 34:713–721. https://doi.org/10.1007/s40259-020-00451-w - DOI - PubMed
    1. Ananthakrishnan AN (2015) Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol 12:205–217. https://doi.org/10.1038/nrgastro.2015.34 - DOI - PubMed
    1. Angelison L, Almer S, Eriksson A, Karling P, Fagerberg U, Halfvarson J, Thörn M, Björk J, Hindorf U, Löfberg R, Bajor A, Hjortswang H, Hammarlund P, Grip O, Torp J, Marsal J, Hertervig E (2017) Long-term outcome of infliximab treatment in chronic active ulcerative colitis: a Swedish multicentre study of 250 patients. Aliment Pharmacol Ther 45:519–532. https://doi.org/10.1111/apt.13893 - DOI - PubMed
    1. Argollo M, Furfaro F, Gilardi D, Roda G, Allocca M, Peyrin-Biroulet L, Danese S (2020) Modulation of sphingosine-1-phosphate in ulcerative colitis. Expert Opin Biol Ther 20:413–420. https://doi.org/10.1080/14712598.2020.1732919 - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources